Affineti Biologics, a New Jersey-based company developing plaque-reducing dental hygiene products, has received a $500k investment from Foundation Venture Capital Group.
The company intends to use the funds to advance its research in the development of therapeutic and diagnostic products.
Affineti has already had positive results from studies for anti-caries and periodontal therapy to reduce plaque, and increase dental hygiene.
Founded by Dr. Daniel Fine, a professor and chair, Department of Oral Biology at UMDNJ-New Jersey Dental School, the company intends to develop products, based on creating hybrid or fusion proteins that adhere to tissues with non-toxic antimicrobial effects.
In the short term, Affineti plans to use these proteins in conditions related to the oral cavity and then expand to include mucosal infections in other sites throughout the body.